New cancer drug ORB-011 tested in early human trial
NCT ID NCT05947474
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested an investigational drug called ORB-011 in 55 adults with advanced solid tumors (cancers that have spread or come back). The main goals were to see if the drug is safe and to find the best dose for future studies. Participants received ORB-011 by IV infusion, and researchers monitored side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORB-011 (a drug given by IV infusion)
What this could lead to
If successful, this trial could identify a safe dose of ORB-011 for further testing in larger studies, potentially leading to a new treatment option for advanced solid tumors.
What could go wrong
This is an early Phase 1 trial with only 55 participants, focused on safety and dosing—not on effectiveness. The drug may not work against tumors or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
MD Anderson Center
Houston, Texas, 77030, United States